David Henry's JCSO podcast, August 2015

Article Type
Changed
Fri, 01/04/2019 - 11:11
Display Headline
David Henry's JCSO podcast, August 2015

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights a Review article on the role of targeted therapy in HIV-positive patients with lung cancer and 2 Original Reports, one on the impact of bladder volume on radiation dose to the rectum in patients with prostate cancer and a second on treatment outcomes in stage IIIA non-small-cell lung cancer in a community cancer center setting. Also discussed are a Commentary by David Cella and Lynne Wagner about re-personalizing precision medicine, and a Feature article on genomic oncology, the foundation of targeted, personalized therapies.  A Community Translations article on the recent approval of the histone deacetylase inhibitor panobinostat demonstrates how a novel mechanism of action has been harnessed to produce a therapy that can extend progression-free survival in patients with relapsed multiple myeloma, and 2 Case Reports document the presentation and treatment of 2 patients with rare conditions – nonislet cell tumor-induced hypoglycemia and drug-induced immune hemolytic anemia.

References

Author and Disclosure Information

Audio / Podcast
Publications
Topics
Legacy Keywords
Personalized medicine, targeted therapy, precision medicine, genomic oncology, patient-reported outcomes, PRO, patient-centeredness, histone deacetylase inhibitor, HDAC, panobinostat, multiple myeloma, Panorama trial, lung cancer, HIV-positive, clinical trials, non-small-cell lung cancer, NSCLC, EGFR mutations, antiretroviral, ARV, prostate cancer, bladder volume, radiation dose, intensity-modulated radiation therapy, IMRT, nonislet cell tumor-induced hypoglycemia, NICTH, Doege-Potter syndrome, insulin-like growth factor, IGF-1, drug-induced immune hemolytic anemia, DIIHA, paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, chronic myeloid leukemia, CML,

Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights a Review article on the role of targeted therapy in HIV-positive patients with lung cancer and 2 Original Reports, one on the impact of bladder volume on radiation dose to the rectum in patients with prostate cancer and a second on treatment outcomes in stage IIIA non-small-cell lung cancer in a community cancer center setting. Also discussed are a Commentary by David Cella and Lynne Wagner about re-personalizing precision medicine, and a Feature article on genomic oncology, the foundation of targeted, personalized therapies.  A Community Translations article on the recent approval of the histone deacetylase inhibitor panobinostat demonstrates how a novel mechanism of action has been harnessed to produce a therapy that can extend progression-free survival in patients with relapsed multiple myeloma, and 2 Case Reports document the presentation and treatment of 2 patients with rare conditions – nonislet cell tumor-induced hypoglycemia and drug-induced immune hemolytic anemia.

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights a Review article on the role of targeted therapy in HIV-positive patients with lung cancer and 2 Original Reports, one on the impact of bladder volume on radiation dose to the rectum in patients with prostate cancer and a second on treatment outcomes in stage IIIA non-small-cell lung cancer in a community cancer center setting. Also discussed are a Commentary by David Cella and Lynne Wagner about re-personalizing precision medicine, and a Feature article on genomic oncology, the foundation of targeted, personalized therapies.  A Community Translations article on the recent approval of the histone deacetylase inhibitor panobinostat demonstrates how a novel mechanism of action has been harnessed to produce a therapy that can extend progression-free survival in patients with relapsed multiple myeloma, and 2 Case Reports document the presentation and treatment of 2 patients with rare conditions – nonislet cell tumor-induced hypoglycemia and drug-induced immune hemolytic anemia.

References

References

Publications
Publications
Topics
Article Type
Display Headline
David Henry's JCSO podcast, August 2015
Display Headline
David Henry's JCSO podcast, August 2015
Legacy Keywords
Personalized medicine, targeted therapy, precision medicine, genomic oncology, patient-reported outcomes, PRO, patient-centeredness, histone deacetylase inhibitor, HDAC, panobinostat, multiple myeloma, Panorama trial, lung cancer, HIV-positive, clinical trials, non-small-cell lung cancer, NSCLC, EGFR mutations, antiretroviral, ARV, prostate cancer, bladder volume, radiation dose, intensity-modulated radiation therapy, IMRT, nonislet cell tumor-induced hypoglycemia, NICTH, Doege-Potter syndrome, insulin-like growth factor, IGF-1, drug-induced immune hemolytic anemia, DIIHA, paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, chronic myeloid leukemia, CML,

Legacy Keywords
Personalized medicine, targeted therapy, precision medicine, genomic oncology, patient-reported outcomes, PRO, patient-centeredness, histone deacetylase inhibitor, HDAC, panobinostat, multiple myeloma, Panorama trial, lung cancer, HIV-positive, clinical trials, non-small-cell lung cancer, NSCLC, EGFR mutations, antiretroviral, ARV, prostate cancer, bladder volume, radiation dose, intensity-modulated radiation therapy, IMRT, nonislet cell tumor-induced hypoglycemia, NICTH, Doege-Potter syndrome, insulin-like growth factor, IGF-1, drug-induced immune hemolytic anemia, DIIHA, paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, chronic myeloid leukemia, CML,

Sections
Article Source

PURLs Copyright

Inside the Article

David Henry's JCSO podcast, July 2015

Article Type
Changed
Fri, 01/04/2019 - 11:11
Display Headline
David Henry's JCSO podcast, July 2015

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a Community Translations article on lenvatinib, which was approved earlier this year for the treatment of patients with advanced differentiated thyroid cancer whose disease has progressed after radioactive iodine therapy. Also in the line-up are two Original Reports, one on health care expenditures associated with depression in adults with cancer and another on maximizing accessibility to and the efficacy of a weekly speech and language therapy service for patients with head and neck cancer who are receiving radiotherapy. A Case Report on a patient with inflammatory metastatic breast cancer with gallbladder metastases, a Feature article on new lung cancer treatments, and a summary of key findings from the 2015 annual meeting of the American Society of Clinical Oncology, round off the podcast.

References

Author and Disclosure Information

Audio / Podcast
Publications
Topics
Legacy Keywords
lenvatinib, differentiated thyroid cancer, DTC, radioactive iodine therapy, health care expenditures, depression, adults with cancer, speech and language therapy, S&L, head and neck cancer, radiotherapy, inflammatory breast cancer, gallbladder metastases, lung cancer

Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a Community Translations article on lenvatinib, which was approved earlier this year for the treatment of patients with advanced differentiated thyroid cancer whose disease has progressed after radioactive iodine therapy. Also in the line-up are two Original Reports, one on health care expenditures associated with depression in adults with cancer and another on maximizing accessibility to and the efficacy of a weekly speech and language therapy service for patients with head and neck cancer who are receiving radiotherapy. A Case Report on a patient with inflammatory metastatic breast cancer with gallbladder metastases, a Feature article on new lung cancer treatments, and a summary of key findings from the 2015 annual meeting of the American Society of Clinical Oncology, round off the podcast.

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses a Community Translations article on lenvatinib, which was approved earlier this year for the treatment of patients with advanced differentiated thyroid cancer whose disease has progressed after radioactive iodine therapy. Also in the line-up are two Original Reports, one on health care expenditures associated with depression in adults with cancer and another on maximizing accessibility to and the efficacy of a weekly speech and language therapy service for patients with head and neck cancer who are receiving radiotherapy. A Case Report on a patient with inflammatory metastatic breast cancer with gallbladder metastases, a Feature article on new lung cancer treatments, and a summary of key findings from the 2015 annual meeting of the American Society of Clinical Oncology, round off the podcast.

References

References

Publications
Publications
Topics
Article Type
Display Headline
David Henry's JCSO podcast, July 2015
Display Headline
David Henry's JCSO podcast, July 2015
Legacy Keywords
lenvatinib, differentiated thyroid cancer, DTC, radioactive iodine therapy, health care expenditures, depression, adults with cancer, speech and language therapy, S&L, head and neck cancer, radiotherapy, inflammatory breast cancer, gallbladder metastases, lung cancer

Legacy Keywords
lenvatinib, differentiated thyroid cancer, DTC, radioactive iodine therapy, health care expenditures, depression, adults with cancer, speech and language therapy, S&L, head and neck cancer, radiotherapy, inflammatory breast cancer, gallbladder metastases, lung cancer

Sections
Article Source

PURLs Copyright

Inside the Article

David Henry's JCSO podcast, June 2015

Article Type
Changed
Fri, 01/04/2019 - 11:11
Display Headline
David Henry's JCSO podcast, June 2015

This month, Dr David Henry of The Journal of Community and Supportive Oncology examines the use olaparib, which was recently approved for the treatment of BRCA-mutated advanced ovarian cancer, as well as four Original Research articles that focus on patient care, support, and quality of life. There’s a comparison of the antiemetic efficacy and safety of palonosetron and ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children; a study that looks at the rationale, dosimetric parameters, and preliminary clinical outcomes in patients who undergo postoperative stereotactic radiosurgery with simultaneous integrated boost for brain metastases; an examination of the impact of nurse navigation on the timeliness of diagnostic medical services in patients with newly diagnosed lung cancer; and a study that draws on a novel approach to improving end-of-life care by measuring patterns of care among recently deceased patients. The podcast concludes with a round-up of some recent studies on cardiovascular disease in oncology, including the toxicity of cancer therapy and treatment guidelines from the American Society of Clinical Oncology.

References

Author and Disclosure Information

Audio / Podcast
Publications
Topics
Legacy Keywords
Olaparib, BRCA-mutated ovarian cancer, palonosetron, ondansetron, chemotherapy-induced nausea and vomiting, CINV, simultaneous integrated boost, SIB, stereotactic radiosurgery, brain metastases, nurse navigation, diagnostic medical services, lung cancer, end-of-life, EoL, cardiovascular disease, CVD, androgen-deprivation therapy, prostate cancer, cerebral microbleeds, CMBs, white matter lesion, WML, superficial vein thrombosis, SVT, deep vein thrombosis, DVT, venous thromboembolism, VTE

Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

This month, Dr David Henry of The Journal of Community and Supportive Oncology examines the use olaparib, which was recently approved for the treatment of BRCA-mutated advanced ovarian cancer, as well as four Original Research articles that focus on patient care, support, and quality of life. There’s a comparison of the antiemetic efficacy and safety of palonosetron and ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children; a study that looks at the rationale, dosimetric parameters, and preliminary clinical outcomes in patients who undergo postoperative stereotactic radiosurgery with simultaneous integrated boost for brain metastases; an examination of the impact of nurse navigation on the timeliness of diagnostic medical services in patients with newly diagnosed lung cancer; and a study that draws on a novel approach to improving end-of-life care by measuring patterns of care among recently deceased patients. The podcast concludes with a round-up of some recent studies on cardiovascular disease in oncology, including the toxicity of cancer therapy and treatment guidelines from the American Society of Clinical Oncology.

This month, Dr David Henry of The Journal of Community and Supportive Oncology examines the use olaparib, which was recently approved for the treatment of BRCA-mutated advanced ovarian cancer, as well as four Original Research articles that focus on patient care, support, and quality of life. There’s a comparison of the antiemetic efficacy and safety of palonosetron and ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children; a study that looks at the rationale, dosimetric parameters, and preliminary clinical outcomes in patients who undergo postoperative stereotactic radiosurgery with simultaneous integrated boost for brain metastases; an examination of the impact of nurse navigation on the timeliness of diagnostic medical services in patients with newly diagnosed lung cancer; and a study that draws on a novel approach to improving end-of-life care by measuring patterns of care among recently deceased patients. The podcast concludes with a round-up of some recent studies on cardiovascular disease in oncology, including the toxicity of cancer therapy and treatment guidelines from the American Society of Clinical Oncology.

References

References

Publications
Publications
Topics
Article Type
Display Headline
David Henry's JCSO podcast, June 2015
Display Headline
David Henry's JCSO podcast, June 2015
Legacy Keywords
Olaparib, BRCA-mutated ovarian cancer, palonosetron, ondansetron, chemotherapy-induced nausea and vomiting, CINV, simultaneous integrated boost, SIB, stereotactic radiosurgery, brain metastases, nurse navigation, diagnostic medical services, lung cancer, end-of-life, EoL, cardiovascular disease, CVD, androgen-deprivation therapy, prostate cancer, cerebral microbleeds, CMBs, white matter lesion, WML, superficial vein thrombosis, SVT, deep vein thrombosis, DVT, venous thromboembolism, VTE

Legacy Keywords
Olaparib, BRCA-mutated ovarian cancer, palonosetron, ondansetron, chemotherapy-induced nausea and vomiting, CINV, simultaneous integrated boost, SIB, stereotactic radiosurgery, brain metastases, nurse navigation, diagnostic medical services, lung cancer, end-of-life, EoL, cardiovascular disease, CVD, androgen-deprivation therapy, prostate cancer, cerebral microbleeds, CMBs, white matter lesion, WML, superficial vein thrombosis, SVT, deep vein thrombosis, DVT, venous thromboembolism, VTE

Sections
Article Source

PURLs Copyright

Inside the Article

David Henry's JCSO podcast, May 2015

Article Type
Changed
Thu, 12/15/2022 - 18:04
Display Headline
David Henry's JCSO podcast, May 2015

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry looks at Original Reports on the treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting; health professionals’ attitudes toward detecting and managing cancer-related anorexia-cachexia syndrome; the factors associated with symptom-related emergency department visits and hospital admissions during ambulatory cancer treatment; and differences in treatment between urban and rural women with hormone receptor-positive early-stage breast cancer. He also discusses a case report on a patient with severe chemotherapy-induced peripheral neuropathy who experienced a significant response to lacosamide, and Community Translations item using blinatumomab for hard-to-treat acute lymphoblastic leukemia.  

References

Author and Disclosure Information

Audio / Podcast
Publications
Topics
Legacy Keywords
blinatumomab, relapsed/ refractory, Philadelphia chromosome-negative, B-cell acute lymphoblastic leukemia,
BCP-ALL, CD19, CD3, dosage-schedule, nab-paclitaxel, metastatic breast cancer, MBC, human epidermal growth factor receptor 2, HER2–negative, anorexia-cachexia syndrome, CACS, non-small-cell lung cancer, NSCLC, symptom distress, quality of life, QoL, side effects, emergency department, ED, hospital admissions, HAs, emergency department visits, EDVs, symptom-related EDVs, sx-EDV/HAs, urban, rural, hormone receptor-positive, breast cancer, lacosamide, anticonvulsant, chemotherapy-induced peripheral neuropathy, CIPN, urothelial carcinoma,
MVAC, methotrexate, vincristine, adriamycin, cisplatin
Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry looks at Original Reports on the treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting; health professionals’ attitudes toward detecting and managing cancer-related anorexia-cachexia syndrome; the factors associated with symptom-related emergency department visits and hospital admissions during ambulatory cancer treatment; and differences in treatment between urban and rural women with hormone receptor-positive early-stage breast cancer. He also discusses a case report on a patient with severe chemotherapy-induced peripheral neuropathy who experienced a significant response to lacosamide, and Community Translations item using blinatumomab for hard-to-treat acute lymphoblastic leukemia.  

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry looks at Original Reports on the treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting; health professionals’ attitudes toward detecting and managing cancer-related anorexia-cachexia syndrome; the factors associated with symptom-related emergency department visits and hospital admissions during ambulatory cancer treatment; and differences in treatment between urban and rural women with hormone receptor-positive early-stage breast cancer. He also discusses a case report on a patient with severe chemotherapy-induced peripheral neuropathy who experienced a significant response to lacosamide, and Community Translations item using blinatumomab for hard-to-treat acute lymphoblastic leukemia.  

References

References

Publications
Publications
Topics
Article Type
Display Headline
David Henry's JCSO podcast, May 2015
Display Headline
David Henry's JCSO podcast, May 2015
Legacy Keywords
blinatumomab, relapsed/ refractory, Philadelphia chromosome-negative, B-cell acute lymphoblastic leukemia,
BCP-ALL, CD19, CD3, dosage-schedule, nab-paclitaxel, metastatic breast cancer, MBC, human epidermal growth factor receptor 2, HER2–negative, anorexia-cachexia syndrome, CACS, non-small-cell lung cancer, NSCLC, symptom distress, quality of life, QoL, side effects, emergency department, ED, hospital admissions, HAs, emergency department visits, EDVs, symptom-related EDVs, sx-EDV/HAs, urban, rural, hormone receptor-positive, breast cancer, lacosamide, anticonvulsant, chemotherapy-induced peripheral neuropathy, CIPN, urothelial carcinoma,
MVAC, methotrexate, vincristine, adriamycin, cisplatin
Legacy Keywords
blinatumomab, relapsed/ refractory, Philadelphia chromosome-negative, B-cell acute lymphoblastic leukemia,
BCP-ALL, CD19, CD3, dosage-schedule, nab-paclitaxel, metastatic breast cancer, MBC, human epidermal growth factor receptor 2, HER2–negative, anorexia-cachexia syndrome, CACS, non-small-cell lung cancer, NSCLC, symptom distress, quality of life, QoL, side effects, emergency department, ED, hospital admissions, HAs, emergency department visits, EDVs, symptom-related EDVs, sx-EDV/HAs, urban, rural, hormone receptor-positive, breast cancer, lacosamide, anticonvulsant, chemotherapy-induced peripheral neuropathy, CIPN, urothelial carcinoma,
MVAC, methotrexate, vincristine, adriamycin, cisplatin
Sections
Article Source

PURLs Copyright

Inside the Article

David Henry's JCSO podcast, April 2015

Article Type
Changed
Thu, 12/15/2022 - 18:04
Display Headline
David Henry's JCSO podcast, April 2015

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights two Original Reports, one on the effectiveness and safety of ipilimumab therapy in advanced melanoma, and another on the feasibility of implementing a community-based randomized trial of yoga for women who are undergoing chemotherapy for breast cancer. Also in the line-up are a Review article on sleep disorders in patients with cancer; a Community Translations examination of palonosetron and netupitant for the prevention of chemotherapy-induced nausea and vomiting in cancer patients; and Case Reports on distant skin metastases as primary presentation of gastric cancer, and sarcoidosis, complete heart block, and warm autoimmune hemolytic anemia in a young woman. The bimonthly New Therapies feature focuses on hard-to-treat tumors, specifically, glioblastoma, bone sarcoma, and liver cancer.

References

Author and Disclosure Information

Audio / Podcast
Publications
Topics
Legacy Keywords
ipilimumab, melanoma, yoga, breast cancer, quality of life, sleep disorders, palonosetron, netupitant, NEPA, chemotherapy-induced nausea and vomiting, CINV, distant skin metastases, gastric cancer, sarcoidosis, complete heart block, warm autoimmune hemolytic anemia, glioblastoma, GBM, bevacizumab, bone sarcoma, liver cancer, nivolumab, pembrolizumab, everolimus
Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights two Original Reports, one on the effectiveness and safety of ipilimumab therapy in advanced melanoma, and another on the feasibility of implementing a community-based randomized trial of yoga for women who are undergoing chemotherapy for breast cancer. Also in the line-up are a Review article on sleep disorders in patients with cancer; a Community Translations examination of palonosetron and netupitant for the prevention of chemotherapy-induced nausea and vomiting in cancer patients; and Case Reports on distant skin metastases as primary presentation of gastric cancer, and sarcoidosis, complete heart block, and warm autoimmune hemolytic anemia in a young woman. The bimonthly New Therapies feature focuses on hard-to-treat tumors, specifically, glioblastoma, bone sarcoma, and liver cancer.

In this month’s podcast for The Journal of Community and Supportive Oncology, Dr David Henry highlights two Original Reports, one on the effectiveness and safety of ipilimumab therapy in advanced melanoma, and another on the feasibility of implementing a community-based randomized trial of yoga for women who are undergoing chemotherapy for breast cancer. Also in the line-up are a Review article on sleep disorders in patients with cancer; a Community Translations examination of palonosetron and netupitant for the prevention of chemotherapy-induced nausea and vomiting in cancer patients; and Case Reports on distant skin metastases as primary presentation of gastric cancer, and sarcoidosis, complete heart block, and warm autoimmune hemolytic anemia in a young woman. The bimonthly New Therapies feature focuses on hard-to-treat tumors, specifically, glioblastoma, bone sarcoma, and liver cancer.

References

References

Publications
Publications
Topics
Article Type
Display Headline
David Henry's JCSO podcast, April 2015
Display Headline
David Henry's JCSO podcast, April 2015
Legacy Keywords
ipilimumab, melanoma, yoga, breast cancer, quality of life, sleep disorders, palonosetron, netupitant, NEPA, chemotherapy-induced nausea and vomiting, CINV, distant skin metastases, gastric cancer, sarcoidosis, complete heart block, warm autoimmune hemolytic anemia, glioblastoma, GBM, bevacizumab, bone sarcoma, liver cancer, nivolumab, pembrolizumab, everolimus
Legacy Keywords
ipilimumab, melanoma, yoga, breast cancer, quality of life, sleep disorders, palonosetron, netupitant, NEPA, chemotherapy-induced nausea and vomiting, CINV, distant skin metastases, gastric cancer, sarcoidosis, complete heart block, warm autoimmune hemolytic anemia, glioblastoma, GBM, bevacizumab, bone sarcoma, liver cancer, nivolumab, pembrolizumab, everolimus
Sections
Article Source

PURLs Copyright

Inside the Article

David Henry's JCSO podcast, March 2015

Article Type
Changed
Fri, 01/04/2019 - 11:10
Display Headline
David Henry's JCSO podcast, March 2015

In his March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses two original research articles that focus on women who have survived cancer, one that looks at the effects of ArginMax on sexual functioning and quality of life in female cancer survivors, and another that examines the need for decision and communication aids among breast cancer survivors. Also included in this month’s line-up of original research is a report on the cost of palliative external beam radiotherapy for bone metastases in patients with prostate cancer and a study of the impact of an electronic medical record intervention on the use of growth factor in patients with cancer. The regular Community Translations column features the recently approved combination therapy, palbociclib plus letrozole, for first-line treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Dr Henry rounds off the podcast with a discussion the Journal Club’s entry, which this month focuses on new approvals, genetic testing, and maintenance therapy in women with ovarian cancer.

References

Author and Disclosure Information

Audio / Podcast
Publications
Legacy Keywords
ArginMax, sexual functioning, quality of life, QoL, cancer survivors, external beam radiotherapy, EBRT, palliative EBRT, bone metastases, prostate cancer, decision aids, communication aids, breast cancer survivors, electronic medical record, EMR, granulocyte colony-stimulating factors, G-CSF, palbociclib, letrozole, estrogen receptor-positive, ER-positive, human epidermal growth factor receptor 2, HER2-negative, advanced breast cancer, ovarian cancer, BRCAPRO, maintenance therapy, disease-free survival, DFS, bevacizumab, platinum-resistant ovarian cancer, pazopanib, olaparib, PARP inhibitor, AURELIA
Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

In his March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses two original research articles that focus on women who have survived cancer, one that looks at the effects of ArginMax on sexual functioning and quality of life in female cancer survivors, and another that examines the need for decision and communication aids among breast cancer survivors. Also included in this month’s line-up of original research is a report on the cost of palliative external beam radiotherapy for bone metastases in patients with prostate cancer and a study of the impact of an electronic medical record intervention on the use of growth factor in patients with cancer. The regular Community Translations column features the recently approved combination therapy, palbociclib plus letrozole, for first-line treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Dr Henry rounds off the podcast with a discussion the Journal Club’s entry, which this month focuses on new approvals, genetic testing, and maintenance therapy in women with ovarian cancer.

In his March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses two original research articles that focus on women who have survived cancer, one that looks at the effects of ArginMax on sexual functioning and quality of life in female cancer survivors, and another that examines the need for decision and communication aids among breast cancer survivors. Also included in this month’s line-up of original research is a report on the cost of palliative external beam radiotherapy for bone metastases in patients with prostate cancer and a study of the impact of an electronic medical record intervention on the use of growth factor in patients with cancer. The regular Community Translations column features the recently approved combination therapy, palbociclib plus letrozole, for first-line treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Dr Henry rounds off the podcast with a discussion the Journal Club’s entry, which this month focuses on new approvals, genetic testing, and maintenance therapy in women with ovarian cancer.

References

References

Publications
Publications
Article Type
Display Headline
David Henry's JCSO podcast, March 2015
Display Headline
David Henry's JCSO podcast, March 2015
Legacy Keywords
ArginMax, sexual functioning, quality of life, QoL, cancer survivors, external beam radiotherapy, EBRT, palliative EBRT, bone metastases, prostate cancer, decision aids, communication aids, breast cancer survivors, electronic medical record, EMR, granulocyte colony-stimulating factors, G-CSF, palbociclib, letrozole, estrogen receptor-positive, ER-positive, human epidermal growth factor receptor 2, HER2-negative, advanced breast cancer, ovarian cancer, BRCAPRO, maintenance therapy, disease-free survival, DFS, bevacizumab, platinum-resistant ovarian cancer, pazopanib, olaparib, PARP inhibitor, AURELIA
Legacy Keywords
ArginMax, sexual functioning, quality of life, QoL, cancer survivors, external beam radiotherapy, EBRT, palliative EBRT, bone metastases, prostate cancer, decision aids, communication aids, breast cancer survivors, electronic medical record, EMR, granulocyte colony-stimulating factors, G-CSF, palbociclib, letrozole, estrogen receptor-positive, ER-positive, human epidermal growth factor receptor 2, HER2-negative, advanced breast cancer, ovarian cancer, BRCAPRO, maintenance therapy, disease-free survival, DFS, bevacizumab, platinum-resistant ovarian cancer, pazopanib, olaparib, PARP inhibitor, AURELIA
Sections
Article Source

PURLs Copyright

Inside the Article

David Henry's JCSO podcast, February 2015

Article Type
Changed
Fri, 01/04/2019 - 11:10
Display Headline
David Henry's JCSO podcast, February 2015

The line-up for David Henry’s monthly podcast for The Journal of Community and Supportive Oncology includes an Original Report in which investigators report complete response rates (no emesis, no rescue medication) APF530, a sustained-release granisetron, during the acute and delayed phases of chemotherapy-induced nausea and vomiting over multiple cycles of the therapy. He also discusses the findings from a study on joint breast and colorectal cancer screenings in medically underserved women, and another in women with self-reported lower limb lymphedema after treatment for gynecological cancers and their use of services. A fourth Original Report examines perceptions about participation in cancer clinical trials in New York state and how increased outreach and a team approach to educating and enrolling patients in trials are important to increase participation and ensure a diverse sample of participants. Finally, a feature article on new therapies looks at the significant challenges – and recent advances – in the treatment of head and neck cancers.

References

Author and Disclosure Information

Audio / Podcast
Publications
Legacy Keywords
Chemotherapy-induced nausea and vomiting, CINV, antiemetic responses, APF530, sustained-release granisetron, breast cancer screening, colorectal cancer screening, underserved women, fecal occult blood test, FOBT, mammogram, nurse support, lower-limb lymphedema, LLL, gynecological cancers, psychosocial symptoms, depression, anxiety, quality of life, clinical trials, participation in cancer trials, head and neck cancers, head and neck squamous cell carcinoma, HNSCC, epidermal growth factor receptor, EGFR, monoclonal antibody, mAb, tyrosine kinase inhibitors, TKIs, tobacco exposure, human papillomavirus, HPV, HPV-16
Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

The line-up for David Henry’s monthly podcast for The Journal of Community and Supportive Oncology includes an Original Report in which investigators report complete response rates (no emesis, no rescue medication) APF530, a sustained-release granisetron, during the acute and delayed phases of chemotherapy-induced nausea and vomiting over multiple cycles of the therapy. He also discusses the findings from a study on joint breast and colorectal cancer screenings in medically underserved women, and another in women with self-reported lower limb lymphedema after treatment for gynecological cancers and their use of services. A fourth Original Report examines perceptions about participation in cancer clinical trials in New York state and how increased outreach and a team approach to educating and enrolling patients in trials are important to increase participation and ensure a diverse sample of participants. Finally, a feature article on new therapies looks at the significant challenges – and recent advances – in the treatment of head and neck cancers.

The line-up for David Henry’s monthly podcast for The Journal of Community and Supportive Oncology includes an Original Report in which investigators report complete response rates (no emesis, no rescue medication) APF530, a sustained-release granisetron, during the acute and delayed phases of chemotherapy-induced nausea and vomiting over multiple cycles of the therapy. He also discusses the findings from a study on joint breast and colorectal cancer screenings in medically underserved women, and another in women with self-reported lower limb lymphedema after treatment for gynecological cancers and their use of services. A fourth Original Report examines perceptions about participation in cancer clinical trials in New York state and how increased outreach and a team approach to educating and enrolling patients in trials are important to increase participation and ensure a diverse sample of participants. Finally, a feature article on new therapies looks at the significant challenges – and recent advances – in the treatment of head and neck cancers.

References

References

Publications
Publications
Article Type
Display Headline
David Henry's JCSO podcast, February 2015
Display Headline
David Henry's JCSO podcast, February 2015
Legacy Keywords
Chemotherapy-induced nausea and vomiting, CINV, antiemetic responses, APF530, sustained-release granisetron, breast cancer screening, colorectal cancer screening, underserved women, fecal occult blood test, FOBT, mammogram, nurse support, lower-limb lymphedema, LLL, gynecological cancers, psychosocial symptoms, depression, anxiety, quality of life, clinical trials, participation in cancer trials, head and neck cancers, head and neck squamous cell carcinoma, HNSCC, epidermal growth factor receptor, EGFR, monoclonal antibody, mAb, tyrosine kinase inhibitors, TKIs, tobacco exposure, human papillomavirus, HPV, HPV-16
Legacy Keywords
Chemotherapy-induced nausea and vomiting, CINV, antiemetic responses, APF530, sustained-release granisetron, breast cancer screening, colorectal cancer screening, underserved women, fecal occult blood test, FOBT, mammogram, nurse support, lower-limb lymphedema, LLL, gynecological cancers, psychosocial symptoms, depression, anxiety, quality of life, clinical trials, participation in cancer trials, head and neck cancers, head and neck squamous cell carcinoma, HNSCC, epidermal growth factor receptor, EGFR, monoclonal antibody, mAb, tyrosine kinase inhibitors, TKIs, tobacco exposure, human papillomavirus, HPV, HPV-16
Sections
Article Source

PURLs Copyright

Inside the Article

David Henry's JCSO podcast, January 2015

Article Type
Changed
Thu, 12/15/2022 - 18:06
Display Headline
David Henry's JCSO podcast, January 2015

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry looks at Original Reports on the comparison of atropine-diphenoxylate and hyoscyamine in lowering the rates of irinotecan-related cholinergic syndrome; the effects of age and comorbidities in the management of rectal cancer in elderly patients at an institution in Portugal; the impact of a telehealth intervention on quality of life and symptom distress in patients with head and neck cancer; and the beneficial effects of animal-assisted visits on quality of life during multimodal radiation-chemotherapy regimens. He also discusses a Research Report in which the authors attempt, possibly for the first time, to quantify radiation exposure from diagnostic procedures in patients with newly diagnosed breast cancer, as well as two feature articles – a round-up of some of the presentations at the 2014 San Antonio Breast Cancer Symposium and a Journal Club presentation of therapies for lymphoproliferative disorders.

References

Author and Disclosure Information

Audio / Podcast
Publications
Topics
Legacy Keywords
atropine-diphenoxylate, hyoscyamine, irinotecan, cholinergic syndrome, rectal cancer, telehealth, quality of life, QoL, symptom distress, head and neck cancer, animal-assisted visits, AAV, multimodal radiation-chemotherapy, radiation exposure, diagnostic procedures, DPs, breast cancer, immunotherapy, pembrolizumab, SOFT trial, Ovarian suppression, tamoxifen, fulvestrant, Hodgkin lymphoma, RESORT trial, chronic lymphocytic leukemia
Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry looks at Original Reports on the comparison of atropine-diphenoxylate and hyoscyamine in lowering the rates of irinotecan-related cholinergic syndrome; the effects of age and comorbidities in the management of rectal cancer in elderly patients at an institution in Portugal; the impact of a telehealth intervention on quality of life and symptom distress in patients with head and neck cancer; and the beneficial effects of animal-assisted visits on quality of life during multimodal radiation-chemotherapy regimens. He also discusses a Research Report in which the authors attempt, possibly for the first time, to quantify radiation exposure from diagnostic procedures in patients with newly diagnosed breast cancer, as well as two feature articles – a round-up of some of the presentations at the 2014 San Antonio Breast Cancer Symposium and a Journal Club presentation of therapies for lymphoproliferative disorders.

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry looks at Original Reports on the comparison of atropine-diphenoxylate and hyoscyamine in lowering the rates of irinotecan-related cholinergic syndrome; the effects of age and comorbidities in the management of rectal cancer in elderly patients at an institution in Portugal; the impact of a telehealth intervention on quality of life and symptom distress in patients with head and neck cancer; and the beneficial effects of animal-assisted visits on quality of life during multimodal radiation-chemotherapy regimens. He also discusses a Research Report in which the authors attempt, possibly for the first time, to quantify radiation exposure from diagnostic procedures in patients with newly diagnosed breast cancer, as well as two feature articles – a round-up of some of the presentations at the 2014 San Antonio Breast Cancer Symposium and a Journal Club presentation of therapies for lymphoproliferative disorders.

References

References

Publications
Publications
Topics
Article Type
Display Headline
David Henry's JCSO podcast, January 2015
Display Headline
David Henry's JCSO podcast, January 2015
Legacy Keywords
atropine-diphenoxylate, hyoscyamine, irinotecan, cholinergic syndrome, rectal cancer, telehealth, quality of life, QoL, symptom distress, head and neck cancer, animal-assisted visits, AAV, multimodal radiation-chemotherapy, radiation exposure, diagnostic procedures, DPs, breast cancer, immunotherapy, pembrolizumab, SOFT trial, Ovarian suppression, tamoxifen, fulvestrant, Hodgkin lymphoma, RESORT trial, chronic lymphocytic leukemia
Legacy Keywords
atropine-diphenoxylate, hyoscyamine, irinotecan, cholinergic syndrome, rectal cancer, telehealth, quality of life, QoL, symptom distress, head and neck cancer, animal-assisted visits, AAV, multimodal radiation-chemotherapy, radiation exposure, diagnostic procedures, DPs, breast cancer, immunotherapy, pembrolizumab, SOFT trial, Ovarian suppression, tamoxifen, fulvestrant, Hodgkin lymphoma, RESORT trial, chronic lymphocytic leukemia
Sections
Article Source

PURLs Copyright

Inside the Article

David Henry's JCSO podcast, December 2014

Article Type
Changed
Fri, 01/04/2019 - 11:10
Display Headline
David Henry's JCSO podcast, December 2014

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses articles on the recent approval of ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression and the “small victories” in honing new therapies for hard-to-treat cancers such as ovarian, melanoma, and pancreatic. Quality of care and patient quality of life are the basis for the 3 Original Reports that Dr Henry addresses: one study looks at the impact of patient navigation on diagnostic resolution in women with abnormal screenings for breast or cervical cancer; a second examines how the information and communication needs of Chinese American women with breast cancer can be channeled into improving quality of life after treatment for cancer; and a third reports on how dignity therapy as an intervention in patients with advanced colorectal cancer can positively affect the quality of end-of-life care, treatment choices, and cost efficiency.

References

Author and Disclosure Information

Audio / Podcast
Publications
Legacy Keywords
ramucirumab, gastric cancer, GEJ adenocarcinoma, gastroesophageal junction adenocarcinoma, Chinese American, breast cancer, survivorship care, patient information needs, patient-provider communication, dignity therapy, colorectal cancer, quality of life, quality of care, end-of-life care, diagnostic resolution, patient navigation, ovarian cancer, melanoma, pancreatic cancer, hard-to-treat cancers, PARP inhibitors, ipilimumab, pembrolizumab, FOLFIRINOX, nab-paclitaxel, erlotinib
Sections
Audio / Podcast
Audio / Podcast
Author and Disclosure Information

Author and Disclosure Information

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses articles on the recent approval of ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression and the “small victories” in honing new therapies for hard-to-treat cancers such as ovarian, melanoma, and pancreatic. Quality of care and patient quality of life are the basis for the 3 Original Reports that Dr Henry addresses: one study looks at the impact of patient navigation on diagnostic resolution in women with abnormal screenings for breast or cervical cancer; a second examines how the information and communication needs of Chinese American women with breast cancer can be channeled into improving quality of life after treatment for cancer; and a third reports on how dignity therapy as an intervention in patients with advanced colorectal cancer can positively affect the quality of end-of-life care, treatment choices, and cost efficiency.

In his monthly podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses articles on the recent approval of ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression and the “small victories” in honing new therapies for hard-to-treat cancers such as ovarian, melanoma, and pancreatic. Quality of care and patient quality of life are the basis for the 3 Original Reports that Dr Henry addresses: one study looks at the impact of patient navigation on diagnostic resolution in women with abnormal screenings for breast or cervical cancer; a second examines how the information and communication needs of Chinese American women with breast cancer can be channeled into improving quality of life after treatment for cancer; and a third reports on how dignity therapy as an intervention in patients with advanced colorectal cancer can positively affect the quality of end-of-life care, treatment choices, and cost efficiency.

References

References

Publications
Publications
Article Type
Display Headline
David Henry's JCSO podcast, December 2014
Display Headline
David Henry's JCSO podcast, December 2014
Legacy Keywords
ramucirumab, gastric cancer, GEJ adenocarcinoma, gastroesophageal junction adenocarcinoma, Chinese American, breast cancer, survivorship care, patient information needs, patient-provider communication, dignity therapy, colorectal cancer, quality of life, quality of care, end-of-life care, diagnostic resolution, patient navigation, ovarian cancer, melanoma, pancreatic cancer, hard-to-treat cancers, PARP inhibitors, ipilimumab, pembrolizumab, FOLFIRINOX, nab-paclitaxel, erlotinib
Legacy Keywords
ramucirumab, gastric cancer, GEJ adenocarcinoma, gastroesophageal junction adenocarcinoma, Chinese American, breast cancer, survivorship care, patient information needs, patient-provider communication, dignity therapy, colorectal cancer, quality of life, quality of care, end-of-life care, diagnostic resolution, patient navigation, ovarian cancer, melanoma, pancreatic cancer, hard-to-treat cancers, PARP inhibitors, ipilimumab, pembrolizumab, FOLFIRINOX, nab-paclitaxel, erlotinib
Sections
Article Source

PURLs Copyright

Inside the Article

David Henry's JCSO podcast, November 2014

Article Type
Changed
Fri, 12/16/2022 - 12:26
Display Headline
David Henry's JCSO podcast, November 2014

Among the items featured in Dr David Henry’s monthly podcast for The Journal of Community and Supportive Oncology, are reports on congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia and on the impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in head and neck cancer patients on cisplatin chemotherapy. Two articles focus on patient quality of life: one examines peripheral neuropathy and its impact on QoL after chemotherapy and another looks at QoL and symptoms after stereotactic body radiotherapy in early-stage lung cancer. There’s also a Case Report about a patient with superior vena cava syndrome as an initial presentation of low-grade follicular lymphoma, a feature article on choice of anesthesia during cancer surgery and patient outcomes, and a comprehensive and informative round-up of ASCO’s 2013-2014 guideline releases, updates, and endorsements.

Publications
Topics
Legacy Keywords
congestive heart failure, induction, anthracycline-based therapy, acute promyelocytic leukemia, impact of aprepitant on emesis control, dose intensity, recurrence-free survival, head and neck cancer, cisplatin chemotherapy, patient quality of life, peripheral neuropathy, QoL, chemotherapy, stereotactic body radiotherapy, early-stage lung cancer, superior vena cava syndrome, low-grade follicular lymphoma, anesthesia, cancer surgery, patient outcomes, and ASCO 2013-2014 guideline releases
Sections

Among the items featured in Dr David Henry’s monthly podcast for The Journal of Community and Supportive Oncology, are reports on congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia and on the impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in head and neck cancer patients on cisplatin chemotherapy. Two articles focus on patient quality of life: one examines peripheral neuropathy and its impact on QoL after chemotherapy and another looks at QoL and symptoms after stereotactic body radiotherapy in early-stage lung cancer. There’s also a Case Report about a patient with superior vena cava syndrome as an initial presentation of low-grade follicular lymphoma, a feature article on choice of anesthesia during cancer surgery and patient outcomes, and a comprehensive and informative round-up of ASCO’s 2013-2014 guideline releases, updates, and endorsements.

Among the items featured in Dr David Henry’s monthly podcast for The Journal of Community and Supportive Oncology, are reports on congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia and on the impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in head and neck cancer patients on cisplatin chemotherapy. Two articles focus on patient quality of life: one examines peripheral neuropathy and its impact on QoL after chemotherapy and another looks at QoL and symptoms after stereotactic body radiotherapy in early-stage lung cancer. There’s also a Case Report about a patient with superior vena cava syndrome as an initial presentation of low-grade follicular lymphoma, a feature article on choice of anesthesia during cancer surgery and patient outcomes, and a comprehensive and informative round-up of ASCO’s 2013-2014 guideline releases, updates, and endorsements.

Publications
Publications
Topics
Article Type
Display Headline
David Henry's JCSO podcast, November 2014
Display Headline
David Henry's JCSO podcast, November 2014
Legacy Keywords
congestive heart failure, induction, anthracycline-based therapy, acute promyelocytic leukemia, impact of aprepitant on emesis control, dose intensity, recurrence-free survival, head and neck cancer, cisplatin chemotherapy, patient quality of life, peripheral neuropathy, QoL, chemotherapy, stereotactic body radiotherapy, early-stage lung cancer, superior vena cava syndrome, low-grade follicular lymphoma, anesthesia, cancer surgery, patient outcomes, and ASCO 2013-2014 guideline releases
Legacy Keywords
congestive heart failure, induction, anthracycline-based therapy, acute promyelocytic leukemia, impact of aprepitant on emesis control, dose intensity, recurrence-free survival, head and neck cancer, cisplatin chemotherapy, patient quality of life, peripheral neuropathy, QoL, chemotherapy, stereotactic body radiotherapy, early-stage lung cancer, superior vena cava syndrome, low-grade follicular lymphoma, anesthesia, cancer surgery, patient outcomes, and ASCO 2013-2014 guideline releases
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica